### Comment:
They already discovered their iPhone. Its cabozantinib which just got approval for 1st line RCC (kidney cancer). They are sitting at 25% market share and outperforming every other TKI in the market. If they can continue to penetrate the market at a comparable rate, they will quadruple revenue and earnings in the next year.

### REPLY:
You got me fag . What is the timeline we are looking at ? When do we expect this bitch to get up to 40-100

### END.